15:20:00 EDT Thu 28 May 2020
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:RHHBY - ROCHE HOLDINGS AG - http://roche.com15:20:00 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RHHBY - Qnot subscribed44.175+1.0852.5762.433,6132,38443.72  44.265  43.7046.00  25.1015:02:5701:0015 min RT 2¢

Recent Trades - Last 10 of 2384
Time ETExPriceChangeVolume
15:03:05Q44.161.07100
15:03:04Q44.161.07300
15:02:57Q44.1751.0851
15:02:56Q44.1751.085101
15:02:39Q44.161.07103
15:02:19Q44.161.07100
15:02:04Q44.161.07100
15:01:54Q44.161.07100
15:01:51Q44.191.10104
15:01:26Q44.161.07100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2020-05-28 01:00U:RHHBYNews ReleaseGenentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia
2020-05-27 01:00U:RHHBYNews ReleasePort Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
2020-05-22 01:00U:RHHBYNews ReleaseNew Longer-Term Data Reinforce Safety of Genentech ’s Satralizumab in Adults and Adolescents With Neuromyelitis Optica Spectrum Disorder (NMOSD)
2020-05-19 16:26U:RHHBYNews ReleaseRoche highly accurate antibody test for COVID-19 goes live at more than 20 initial lab sites in the US
2020-05-19 03:05U:RHHBYNews ReleaseVividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
2020-05-18 15:30U:RHHBYNews ReleaseFDA Approves Genentech ’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer
2020-05-13 17:00U:RHHBYNews ReleaseGenentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO
2020-05-12 10:02U:RHHBYNews ReleaseRoche launches new exome and custom KAPA Target Enrichment portfolio for translational and clinical research applications in sequencing
2020-05-07 01:00U:RHHBYNews ReleaseNew Data at the ASCO20 Virtual Scientific Program Reflects Genentech ’s Commitment to Accelerating Progress in Cancer Care